Instil Bio, Inc. - TIL STOCK NEWS

Instil Bio, Inc. (Nasdaq: TIL) has voluntarily paused enrollment in its ITIL-168 and ITIL-306 clinical trials due to a decrease in the successful manufacturing rate of ITIL-168, impacting patient dosing. Despite this, no regulatory agencies have placed the trials on clinical hold. The company is conducting a comprehensive manufacturing analysis and plans to implement corrective actions. Instil confirmed its cash runway through 2025, contingent on a potential sale-leaseback of its Tarzana facility, and intends to provide a manufacturing update by early Q1 2023.

Instil Bio (Nasdaq: TIL) has commenced a Phase 1 study of ITIL-306, a groundbreaking TIL therapy targeting folate receptor alpha, designed to enhance tumor infiltrating lymphocyte (TIL) activity. The first patient, suffering from treatment-refractory non-small cell lung cancer, has been dosed. CoStAR-TIL therapy aims to improve TIL efficacy, potentially reducing reliance on high-dose interleukin-2. Initial clinical data is anticipated in 2023, marking a significant advancement in TIL therapy aimed at achieving durable remissions in challenging solid tumors.

Instil Bio, Inc. (Nasdaq: TIL), a clinical-stage biopharmaceutical company specializing in tumor infiltrating lymphocyte (TIL) therapies, will participate in the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 10:30 a.m. ET. This event includes a company presentation and Q&A session. Investors can access a live webcast of the presentation under the 'News & Events' section on the company's website. Instil is developing therapies for advanced melanoma and other solid tumors, leveraging its proprietary manufacturing processes for its lead product candidate, ITIL-168.

DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio (Nasdaq: TIL) has announced its participation at the Morgan Stanley 20th Annual Global Healthcare Conference. The fireside chat will take place on September 12, 2022, at 2:50 p.m. ET. Investors can access a live webcast of the presentation on the company’s website, with an archived version available shortly after the event. Instil Bio focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, including its lead candidate ITIL-168 for advanced melanoma.

Instil Bio (NASDAQ: TIL) has appointed Tim Moore as Chief Operating Officer, bringing over 30 years of experience in biopharmaceutical manufacturing and operations to the company. Previously, Moore played a key role in launching Yescarta at Kite Pharma and led PACT Pharma as President and COO. CEO Bronson Crouch emphasized the addition of Moore to their executive team as a strategic move to enhance their capabilities in cell therapy development. Instil's ongoing focus is on advancing TIL therapies, especially ITIL-168 and ITIL-306, for treating solid tumors.

Instil Bio, Inc. reported its Q2 2022 results, highlighting continued enrollment in its DELTA-1 clinical trial of ITIL-168 for advanced melanoma, with top-line data expected in early 2024. The company aims to extend its cash runway into 2025, supported by a potential sale-leaseback of its Tarzana, CA manufacturing site. Key initiatives include the initiation of Phase 1 trials for ITIL-306 and ITIL-168 in combination with pembrolizumab for various cancers. However, Instil reported a net loss of $58.99 million, with total cash and equivalents down to $354.6 million from $454.1 million year-over-year.

Instil Bio has received FDA IND clearance for its first genetically-engineered CoStAR-TIL therapy, ITIL-306, targeting non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and ovarian cancer. The Phase 1 clinical study will enroll its first patient soon, utilizing a novel regimen that eliminates post-infusion IL-2. Data to be presented at the 2022 ASCO Annual Meeting demonstrates CoStAR T cells' enhanced expansion and tumor control without the need for high-dose IL-2. This innovation aims to improve the safety and efficacy of TIL treatments.

Instil Bio (Nasdaq: TIL) announced promising results from genomic analyses of tumor-infiltrating lymphocyte (TIL) therapies for metastatic melanoma. An objective response rate (ORR) of 67% was observed in 14 out of 21 patients. Key findings correlate tumor response with TIL clonal expansion and specific T cell populations. The results, showcasing the analytical advances in TIL therapy, will be presented at the ASGCT Annual Meeting on May 18, 2022. The research aims to enhance TIL efficacy, providing insights into anti-cancer therapies.

Instil Bio (Nasdaq: TIL) reported its Q1 2022 financial results, highlighting a cash position of $61.5 million and marketable securities of $318 million. The company is focused on advancing its tumor infiltrating lymphocyte (TIL) therapies, with ongoing enrollment in the DELTA-1 trial targeting advanced melanoma, aiming for top-line data in 2023. Additionally, a Phase 1 study of ITIL-306 is set to start in Q2 2022. The cash runway is projected to extend into 2024, backed by significant preclinical data presentations scheduled for ASCO 2022.